Related Experiment Video
Updated: Jan 17, 2026
07:01
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
9.4K
New frontier for epilepsy treatment through targeting cellular senescence
Stephen Temitayo Bello1, Md Rajdoula Rafe2, Fengwen Huang1
1Department of Neuroscience, City University of Hong Kong, Kowloon, Hong Kong Special Administrative Region; Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, New Territories, Hong Kong, China.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|September 24, 2025
Summary
Cellular senescence, a process halting cell growth, is linked to epilepsy. Understanding senescence-associated secretory phenotype (SASP) and senolytics may offer new epilepsy treatment strategies.
Area of Science:
- Neurology
- Cell Biology
- Gerontology
Background:
- Epilepsy affects 1-2% of the global population, necessitating improved therapeutic strategies.
- Cellular senescence, a state of irreversible growth arrest, is implicated in various neurological disorders, including epilepsy.
- A deeper understanding of cellular senescence's role in epilepsy is crucial for developing effective treatments.
Purpose of the Study:
- To review the mechanisms driving cellular senescence and its associated secretory phenotype (SASP).
- To explore the link between cellular senescence and epilepsy development and progression.
- To discuss senolytics and senomorphics as potential therapeutic interventions for epilepsy.
Main Methods:
- Literature review of cellular senescence mechanisms and pathways.
- Analysis of the senescence-associated secretory phenotype (SASP) and its inflammatory effects.
- Examination of cell types, including brain cells, undergoing senescence in the context of epilepsy.
Main Results:
- Cellular senescence and SASP contribute to inflammation and tissue dysfunction relevant to epilepsy.
- Specific cellular senescence mechanisms and pathways are associated with epilepsy development.
- Potential biomarkers linking cellular senescence and epilepsy have been identified.
Conclusions:
- Cellular senescence is a significant factor in epilepsy development and progression.
- Targeting cellular senescence pathways, including SASP, offers novel therapeutic avenues for epilepsy.
- Senolytics and senomorphics show promise for future epilepsy treatment strategies.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
1.2K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
01:15Neurogenesis and Regeneration of Nervous Tissue
1.6K
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
1.6K
01:22Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
01:30Electroconvulsive Therapy
902
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
902
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
827
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
827